NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169625&from=3 CLASS PERIOD: March 4, 2024 to May ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169614&from=4 ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=168877&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MO ...

Sep 23, 2025 7:20 PM Eastern Daylight Time SVRA NOTICE: Savara Inc. Investors Urged to Contact Kirby McInerney LLP About Securities Fraud Lawsuit Share NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Savara Inc. ("Savara†or the "Company†) (NASDAQ:SVRA) investors of the November 7, 2025 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Savara securities between March 7, 2024 through May 23, 2025 ("the Class Period†). Follow th ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submissio ...

公司相关法律事件 - Gross Law Firm向Savara Inc (NASDAQ: SVRA)股东发布集体诉讼通知 涉及2024年3月4日至2025年5月23日期间购入股票的投资者[1][3] - 指控内容包括公司对MOLBREEVI BLA的化学制造与控制信息披露不足 FDA不太可能以当前形式批准该药物治疗肺泡蛋白沉积症的申请[3] - 公司被指需额外融资 因MOLBREEVI监管批准延迟可能影响资金状况 此前公开声明被指控存在重大虚假和误导性内容[3] 诉讼程序安排 - 股东参与截止日期为2025年11月7日 需通过指定链接完成登记[4] - 登记股东将接入案件生命周期监控系统 原告代表申请同步截止[4] - 律所提供免费参与通道 不要求必须成为原告代表即可获得赔偿资格[1][4]

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submissio ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost. If you suffered a loss on your Savara investments, you have until November 7, 2025 to request lead plaintiff appointment. Follow the ...

Accessibility StatementSkip Navigation https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=167315&wire=4 SVRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) a ...